Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures.

ABSTRACT: Recent preclinical and clinical studies demonstrate that three functionally different compounds, the NMDA receptor channel blocker ketamine, mGlu_2/3 receptor antagonist LY341495, and NMDA receptor glycine site agent GLYX-13 produce rapid and long lasting antidepressant effects. Furthermore, these agents are reported to stimulate ERK and mTORC1 signaling in brain. Here we used rat primary cortical culture neurons to further examine the cellular actions of these agents. The results demonstrate that low concentrations of all three compounds rapidly increase levels of the phosphorylated and activated forms of ERK and a downstream target of mTORC1, p70S6 kinase, in a concentration and time dependent manner. In addition, each compound rapidly increases BDNF release into the culture me

SUBMITTER: Lepack AE 

PROVIDER: S-EPMC5075989 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature